CORDIS
EU research results

CORDIS

English EN
Catalyst Cascade Reactions in ‘One-Flow’ within a Compartmentalized, Green-Solvent ‘Digital Synthesis Machinery’ – End-to-End Green Process Design for Pharmaceuticals

Catalyst Cascade Reactions in ‘One-Flow’ within a Compartmentalized, Green-Solvent ‘Digital Synthesis Machinery’ – End-to-End Green Process Design for Pharmaceuticals

Objective

"ONE-FLOW translates ‘vertical hierarchy’ of chemical multistep synthesis with its complex machinery into self-organising ‘horizontal hierarchy’ of a compartmentalized flow reactor system – a biomimetic digital flow cascade machinery with just one reactor passage. To keep horizontal hierarchy manageable, orthogonality among the consecutive reactions needs to be increased. The winning point of nature is to have invented catalytic cascades. ONE-FLOW will uplift that by enabling the best bio- and chemocatalysts working hand in hand. 4 synthetic flow cascades ('metabolic pathways’) and 1 flow cascade driven by automated intelligence ('signaling pathway') will produce 4 Top-list 2020 drugs. ‘The Compartmentalized Smart Factory’ will develop organic, inorganic, and mechanical compartmentalization. ‘The Green-Solvent Spaciant Factory’ will fluidically allow the use of interim reaction spaces (spaciants). ‘The Systemic Operations Factory’ will aim at full orthogonality using data-base guided ultimate process harmonization. ‘The Digital Machine-to-Machine Factory’ will alter the landscape of chemical synthesis by virtue of the ""Internet of Chemical Things"". Automated machine-to-machine data transfer enables relegation of process monitoring to central computer systems under the oversight of chemists. ‘The Fully Continuous Integrated Factory’ will develop a commercial platform technology under the auspices of sustainability-driven process-design evaluation, making amenable the new kind of processing to all chemists. ONE-FLOW has massive impact potential: i) 38 billion Euro production cost saving; ii) 300 million EUR cost saving per drug; iii) address diseases with 500 billion Euro medication costs; iv) increase market share of emerging high-tech SME players by 10% in 10 years; v) open new windows of opportunity (personalized medicine) with 200-500 million Euro per disease; and vi) achieve 40% female share on a senior scientist level (ONE-FLOW: 34% senior, 57% junior)."

Coordinator

TECHNISCHE UNIVERSITEIT EINDHOVEN

Address

Groene Loper 3
5612 Ae Eindhoven

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 197 023,75

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

TECHNISCHE UNIVERSITAET GRAZ

Austria

EU Contribution

€ 404 940

TECHNISCHE UNIVERSITEIT DELFT

Netherlands

EU Contribution

€ 482 690

UNIVERSITAET BIELEFELD

Germany

EU Contribution

€ 401 750

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 359 001,25

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 350 000

UNIVERSITY OF HULL

United Kingdom

EU Contribution

€ 344 672,50

MICROINNOVA ENGINEERING GMBH

Austria

EU Contribution

€ 356 750

Project information

Grant agreement ID: 737266

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 3 896 827,50

  • EU contribution

    € 3 896 827,50

Coordinated by:

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands